Full Press Release Details
Accessibility: Skip TopNav
Summit Therapeutics plc : Holding(s) in Company
November 30, 2015 13:05 ET
Summit Therapeutics plc
Summit Therapeutics plc
| TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i | ||
| 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | Summit Therapeutics PLC Sedol BN40HZ0 | |
| 2 Reason for the notification (please tick the appropriate box or boxes): | ||
| An acquisition or disposal of voting rights | ||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||
| An event changing the breakdown of voting rights | ||
| Other (please specify): | Voluntary baseline disclosure upon implementation of amendments to the Transparency Directive | X |
| 3. Full name of person(s) subject to the notification obligation: iii | 1 Lansdowne Partners International Limited 2 Lansdowne Partners Limited 3 Lansdowne Partners (UK) LLP | |
| 4. Full name of shareholder(s) (if different from 3.):iv | HSBC Client Holdings Nominee (UK) Ltd, HSBC Bank Plc Lansdowne Markets (Registered Shareholders) | |
| 5. Date of the transaction and date on which the threshold is crossed or reached: v | 26/11/2015 | |
| 6. Date on which issuer notified: | 30/11/2015 | |
| 7. Threshold(s) that is/are crossed or reached: vi, vii | Voluntary baseline disclosure upon implementation of amendments to the Transparency Directive |
| 8. Notified details: | |||||||
| A: Voting rights attached to shares viii, ix | |||||||
| Class/type of shares if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||
| Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||
| Direct | Direct xi | Indirect xii | Direct | Indirect | |||
| Ordinary Shares | 11,077,170 | 11,077,170 | 11,077,170 | 18.07% | |||
| GB00BN40HZ01 | |||||||
| B: Qualifying Financial Instruments | |||||||
| Resulting situation after the triggering transaction | |||||||
| Type of financial instrument | Expiration date xiii | Exercise/ Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights | |||
| American Depositary Shares (ADS) | N/A | N/A | 4,650,000 | 7.59% | |||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | |||||||
| Resulting situation after the triggering transaction | |||||||
| Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to | % of voting rights xix, xx | ||
| Nominal | Delta | ||||||
| Total (A+B+C) | |||||||
| Number of voting rights | Percentage of voting rights | ||||||
| 15,727,170 | 25.66% |
| 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi | |
| Lansdowne Partners International Limited is the parent undertaking of Lansdowne Partners Limited which is the First Corporate Member of Lansdowne Partners (UK) LLP | |
| Proxy Voting: | |
| 10. Name of the proxy holder: | |
| 11. Number of voting rights proxy holder will cease to hold: | |
| 12. Date on which proxy holder will cease to hold voting rights: | |
| 13. Additional information: | Based on total voting rights of 61,290,740 |
| 14. Contact name: | Ruari Paton |
| 15. Contact telephone number: | +44 020 7290 5500 |